ArticleAntimicrobial agents and chemotherapy2000
Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria.
Article in Antimicrobial agents and chemotherapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 87 citations in OpenAlex.
- Development and in vitro evaluation of teicoplanin PEGylated (TEC-PEGylated) niosomes for antimicrobial and anti-biofilm activity against vancomycin-intermediate Staphylococcus aureus (VISA).BMC biotechnology · 2026Article
- Review
- Formulation and Characterization of Teicoplanin Niosomal Gel for Healing Chronic Wounds Infected with Methicillin-ResistantGels (Basel, Switzerland) · 2025Article
- The Inhibitory Effect of Niosome Containing Myrtenol as an Innovative Approach to Combat Methicillin-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- Focused Insights into Liposomal Nanotherapeutics for Antimicrobial Treatment.Current medicinal chemistry · 2025Review
- The Role ofPharmaceutics · 2024Review
- Antibacterial and antibiofilm potentials of vancomycin-loaded niosomal drug delivery system against methicillin-resistant Staphylococcus aureus (MRSA) infections.BMC biotechnology · 2024Article
- Investigation of enhanced intracellular delivery of nanomaterials modified with novel cell-penetrating zwitterionic peptide-lipid derivatives.Drug delivery · 2023Article
- Liposome-Based Antibacterial Delivery: An Emergent Approach to Combat Bacterial Infections.ACS omega · 2023Review
- Bacteriomimetic Liposomes Improve Antibiotic Activity of a Novel Energy-Coupling Factor Transporter Inhibitor.Pharmaceutics · 2021Article
- Liposomes as Antibiotic Delivery Systems: A Promising Nanotechnological Strategy against Antimicrobial Resistance.Molecules (Basel, Switzerland) · 2021Review
- Encapsulation ofFoods (Basel, Switzerland) · 2021Article
- Rhamnolipid-Based Liposomes as Promising Nano-Carriers for Enhancing the Antibacterial Activity of Peptides Derived from Bacterial Toxin-Antitoxin Systems.International journal of nanomedicine · 2021Article
- Nanotools for Sepsis Diagnosis and Treatment.Advanced healthcare materials · 2021Review
- Advances in nanomedicine for the treatment of ankylosing spondylitis.International journal of nanomedicine · 2019Review
- Evaluation of the protective effects of curcuminoid (curcumin and bisdemethoxycurcumin)-loaded liposomes against bone turnover in a cell-based model of osteoarthritis.Drug design, development and therapy · 2015Article
- S-thanatin functionalized liposome potentially targeting on Klebsiella pneumoniae and its application in sepsis mouse model.Frontiers in pharmacology · 2015Article
- Distribution and Inhibition of Liposomes on Staphylococcus aureus and Pseudomonas aeruginosa Biofilm.PloS one · 2015Article
- Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia.Pharmaceutical research · 2012Article
- Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles.International journal of nanomedicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Different ofloxacin-loaded unilamellar vesicles were prepared by the extrusion technique, and their antimicrobial activities were determined in comparison to those of the free drug by means of MIC determinations with both American Type Culture Collection standards and wild-type bacterial strains (six strains of Enterococcus faecalis, seven strains of Escherichia coli, six strains of Staphylococcus aureus, and six strains of Pseudomonas aeruginosa). The accumulation of ofloxacin and liposome-ofloxacin was measured by determining the amount of the drug inside the bacteria as a function of time. Encapsulated fluoroquinolone yielded MICs which were at least twofold lower than those obtained with the free drug. In particular, liposomes made up of dimyristoylphosphatidylcholine-cholesterol-dipalmitoylphosphatidylser ine and dimyristoylphosphatidylcholine-cholesterol-dihexadecylphosphate (4:3:4 molar ratio) provided the best improvement in antimicrobial activity against the various bacterial strains investigated. The liposome formulation produced higher intracellular fluoroquinolone concentrations than those achieved simultaneously with the free drug in both E. coli and P. aeruginosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.